Literature DB >> 32458364

A Structured Approach for Safely Reintroducing Bariatric Surgery in a COVID-19 Environment.

Christopher R Daigle1, Toms Augustin2, Rickesha Wilson3, Karen Schulz3, Alisan Fathalizadeh3, Amy Laktash1, Marita Bauman1, Kalman P Bencsath4, Walter Cha4, John Rodriguez3, Ali Aminian5.   

Abstract

Due to the profound effect of novel coronavirus disease 2019 (COVID-19) on healthcare systems, surgical programs across the country have paused surgical operations and have been utilizing virtual visits to help maintain public safety. For those who treat obesity, the importance of bariatric surgery has never been more clear. Emerging studies continue to identify obesity and several other obesity-related comorbid conditions as major risk factors for a more severe COVID-19 disease course. However, this also suggests that patients seeking bariatric surgery are inherently at risk of suffering severe complications if they were to contract COVID-19 in the perioperative period. The aim of this protocol is to utilize careful analysis of existing risk stratification for bariatric patients, novel COVID-19-related data, and consensus opinion from multiple academic bariatric centers within our organization to help guide the reanimation of our programs when appropriate and to use this template to prospectively study this risk-stratified population in real time. The core principles of this protocol can be applied to any surgical specialty.

Entities:  

Keywords:  Bariatric surgery; COVID-19; Complications; Coronavirus; Pneumonia; Safety

Mesh:

Year:  2020        PMID: 32458364      PMCID: PMC7250538          DOI: 10.1007/s11695-020-04733-8

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   3.479


Introduction

In the USA, non-urgent surgical procedures have been postponed due to the novel coronavirus disease 2019 (COVID-19) pandemic with the hopes of preserving much-needed equipment and minimizing exposure to patients and staff. For this reason, bariatric programs across the country have paused surgical operations and have been utilizing virtual visits to maintain multidisciplinary care pathway momentum and fulfill insurance requirements. Superimposed on this historic public health threat is a looming economic disaster stemming from essential social distancing and the effective interruption of the global economy. The resulting economic and political pressures are forcing Federal and State officials to consider reopening the country, including phasing back in elective, non-urgent surgery [1, 2]. For those who treat obesity and associated metabolic disease, the importance of bariatric surgery has never been more clear. Emerging studies continue to identify obesity and several other obesity-related comorbid conditions as major risk factors for a more severe COVID-19 disease course, suggesting yet another addition to the long list of afflictions related to the global obesity epidemic [3-5]. However, this also suggests that patients seeking bariatric surgery are inherently at risk of suffering severe complications if they were to be undiagnosed asymptomatic or pre-symptomatic carriers of COVID-19 at the time of surgery or contract it in the perioperative period. While it is reasonable to assume that the beneficial effects of surgical therapy for obesity and related conditions could significantly mitigate the severity of COVID-19 infection, that must be carefully balanced against many unknown perioperative variables in a truly novel and dynamic situation. There is no established playbook for this. There is no litany of research to help guide our field through the inevitable challenges we will collectively face as we try to carefully usher our patients back to the critical therapies they need. A simple reopening of the floodgates without careful attention to triaging based on perceived risk could be disastrous for patients, staff, and local hospital infrastructure. To our knowledge, there are currently no reports helping to establish safe practice guidelines for reintroducing bariatric surgery to our communities in a COVID-19 environment. The aim of this protocol is to utilize careful analysis of existing risk stratification for bariatric patients, novel COVID-19-related data, and thoughtful consensus opinion from multiple bariatric centers within the Cleveland Clinic Ohio Health System to help guide the reanimation of our programs when appropriate. This template will then be used to prospectively study this risk-stratified population in real time. We hypothesize that the core principles of such a protocol are useful for any surgical specialty considering careful reintroduction of surgical therapies.

Methods

In developing our proposed tiered protocol (Table 1), we aimed to align with established bariatric risk data and prediction models, recent guidance principles from the American College of Surgeons, and consensus among eight bariatric surgeons in the four Ohio bariatric programs within our organization, including Cleveland Clinic Main Campus, Fairview Hospital, Hillcrest Hospital, and Akron General [2, 6–8]. The consensus opinion was important as previously established risk prediction models and calculators do not account for COVID-19 risk nor the important effects of certain outcomes on healthcare resource utilization during a pandemic. The goal of the safety-centered tiered approach is to adhere to the following key principles, understanding that these recommendations will have to be individualized in each practice setting based on resources and the status of patients, surgeons, centers, and regions:
Table 1

Risk stratification for reintroducing bariatric surgery after the peak of COVID-19 at the Cleveland Clinic

ConditionTier 1Tier 2Tier 3
Low riskIntermediate riskHigh risk
Must meet all conditions belowIf not considered as tier 1 and tier 3Other eligibility criteria are listed belowIf meets any of these conditions below
Type of surgeryPrimary bariatric procedure without other major concurrent procedures

Lower risk revisional procedures:

- Conversion of gastric band or sleeve to other procedures

- Revisional surgery in patients with prior open bariatric surgery
- Conversion of VBG to other procedures
- Concurrent procedures such as paraesophageal hernia repair
- Procedures with higher than average risk for conversion to open surgery, blood transfusion, and prolonged length of stay (e.g., hostile abdomen)
Suggested age cutoff< 60 years≥ 60 years
Suggested BMI cutoff< 55 kg/m2≥ 55 kg/m2
ASA classNo ASA class 4
MobilityNo mobility restriction
DiabetesNo diabetes or controlled type 2 diabetes

- Poorly controlled diabetic (HbA1c > 8%)

- Need for high-dose insulin

- Type 1 diabetes

HypertensionNo hypertension or controlled (< 140/90 mmHg) with one or two antihypertensive agents
Cardiac diseaseNo underlying heart disease

Stable heart disease:

- Stable coronary artery disease

- Controlled atrial fibrillation or other arrhythmias

Significant history of heart disease:

- Previous myocardial infarction

- Heart failure

- Ejection fraction < 40%

- Previous cardiac stents requiring continuing perioperative antiplatelet medications

Lung diseaseNo underlying lung diseaseMildly impaired pulmonary function tests (FEV1 ≥ 80% predicted value)

- Moderately or severely impaired pulmonary function tests (FEV1 < 80% of predicted value)

- Need for home oxygen

Obstructive sleep apneaNo severe OSA (AHI ≥ 30)
Renal diseaseNo CKD stage 3, 4, or 5On dialysis
Liver diseaseCirrhosis ± portal hypertension
Immunosuppression including steroidsNot on immunosuppressive medicationsOn immunosuppressive medications
AnticoagulantNot on anticoagulant
Cleveland clinic cases to be scheduled (N = 98)*
  N (%)38 (39%)24 (25%)36 (37%)
  Age (years), mean ± SD41.1 ± 8.448.3 ± 7.954.5 ± 12.0
  BMI (kg/m2), mean ± SD44.4 ± 4.443.3 ± 5.149.0 ± 10.1
  Bariatric procedures
    SG15519
    RYGB231514
    DS010
    SG to RYGB030
    RYGB and HHR002
    Open reversal of RYGB001

AHI apnea hypopnea index, ASA American Society of Anesthesiologists, BMI body mass index, CKD chronic kidney disease, DS duodenal switch, FEV1 forced expiratory volume in 1 s, HbA1c glycated hemoglobin, HHR hiatal hernia repair, OSA obstructive sleep apnea, RYGB Roux-en-Y gastric bypass, SG sleeve gastrectomy, VBG vertical banded gastroplasty

*As of April 20, 2020

Break down local patient population into reasonable risk tiers based on local patient and resource characteristics, as suggested in Table 1 Start cases in the lowest risk group (tier 1) with reasonable expectation of rapid discharge from the inpatient setting and having less risk of protracted postoperative course if they develop COVID-19 Consider slower than average case volumes initially (for example, ~ 50% typical volume) to ensure real-time safety analysis and mitigate unknown risk Suggest strict social distancing for 2 weeks before bariatric surgery to limit exposure Preoperative COVID-19 testing in all prospective patients (depending on local availability) as close to surgery as possible with strict quarantine between testing date and surgery date Consider adjunctive preoperative chest CT scan if COVID-19 status, interval exposure risk, or clinical picture is unclear Constant monitoring and analysis of real-time data before transitioning to the next tier or continuing with the current tier if outcome data is of concern Heavy reliance on outpatient-based postoperative care (virtual or in-person), including preemptive hydration clinics, to avoid unnecessary postoperative emergency room visits or inpatient admission Risk stratification for reintroducing bariatric surgery after the peak of COVID-19 at the Cleveland Clinic Lower risk revisional procedures: - Conversion of gastric band or sleeve to other procedures - Poorly controlled diabetic (HbA1c > 8%) - Need for high-dose insulin - Type 1 diabetes Stable heart disease: - Stable coronary artery disease - Controlled atrial fibrillation or other arrhythmias Significant history of heart disease: - Previous myocardial infarction - Heart failure - Ejection fraction < 40% - Previous cardiac stents requiring continuing perioperative antiplatelet medications - Moderately or severely impaired pulmonary function tests (FEV1 < 80% of predicted value) - Need for home oxygen AHI apnea hypopnea index, ASA American Society of Anesthesiologists, BMI body mass index, CKD chronic kidney disease, DS duodenal switch, FEV1 forced expiratory volume in 1 s, HbA1c glycated hemoglobin, HHR hiatal hernia repair, OSA obstructive sleep apnea, RYGB Roux-en-Y gastric bypass, SG sleeve gastrectomy, VBG vertical banded gastroplasty *As of April 20, 2020 All patients with pre-existing insurance approval for bariatric surgery from the four participating centers were then partitioned into one of the three tiers based on the criteria in Table 1. Demographic data of the cohort in each tier were extracted and analyzed to help predict the surgical risk and resource utilization needs. Categorical and continuous variables were reported as frequencies (%) and mean ± standard deviation (SD), respectively.

Results

We identified 98 patients between our four Ohio bariatric programs who had already obtained insurance approval for their bariatric procedure and were ready to schedule. The cohort had a mean age of 47.8 ± 11.3 years, mean body mass index (BMI) of 45.8 ± 7.6 kg/m2, and 80.6% (n = 79) were female. Planned primary procedures included Roux-en-Y gastric bypass (n = 52), sleeve gastrectomy (n = 39), and duodenal switch (n = 2). There were 2 cases of gastric bypass with associated hiatal hernia repair and 4 revisional procedures. Detailed results of the specific tiered variables and the effect that had on the allocation of the cohort can be found in Table 1. Patients were categorized to tier 1 (low risk, 39%), tier 2 (intermediate risk, 25%), and tier 3 (high risk, 37%) based on their perioperative risk for future surgical scheduling.

Discussion

There is still much that remains unknown about COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). What we do know is that the pathogen typically has a median incubation period of 4 days (range, 2–7), patients needing medical attention tend to present to hospital 7 days after onset and need for intensive care unit (ICU) level care is at around day 10. Patients in the ICU require much longer periods of time than typical ICU patients and carry staggering mortality rates, especially once they require invasive ventilation. SARS-CoV-2 is a highly contagious pathogen with significant asymptomatic carrier rates and emerging opinion that people are likely highly contagious before ever exhibiting symptoms. For this reason, COVID-19 has rapidly become a once-in-a-generation global pandemic capable of quickly overrunning public health infrastructure [9-12]. Initial reports out of China suggested high sensitivities for CT chest in diagnosing COVID-19 (98% sensitivity) but subsequent reviews of the literature have brought that practice into question. Diagnosis can be confirmed using nasal and pharyngeal swab specimens to perform sequencing or reverse transcriptase–polymerase chain reaction (RT-PCR) for SARS-CoV-2 and sensitivities in these developing protocols continue to improve [13-15]. The accuracy of the RT-PCR in the postoperative period is unknown. The profound metabolic effects of bariatric surgery are well known [16]. It is easy to imagine a scenario where the benefits of surgery could feasibly mitigate some of the reported major COVID-19 risk factors that are so prevalent in bariatric patient populations, like type 2 diabetes, hypertension, chronic lung disease, and the pro-inflammatory obesity state itself. However, emerging reports demonstrate significant mortality rates in patients who underwent elective surgery during the early phases of the pandemic and unknowingly had COVID-19. Furthermore, it is unknown if surgical stress or perioperative physiological changes can increase the risk of contracting or exacerbating COVID-19 infection and management of higher BMI patients with multiple cardiopulmonary comorbidities who develop COVID-19 pneumonia postoperatively would be extremely challenging [17, 18]. Although the current practice of bariatric surgery is very safe, known complications, such as postoperative bleeding, anastomotic leak, or pulmonary embolism, could significantly increase resource utilization, length of hospital stay, and thus, absolute time for possible exposure to COVID-19 in the hospital. Elective surgery on patients with undetected asymptomatic and pre-symptomatic COVID-19 may lead to transmission of COVID-19 to healthcare providers and contamination of crucial operating room infrastructure. Similarly, bariatric surgical patients may acquire the infection during their hospital stay [10, 18, 19]. There are many approaches to prioritizing bariatric patients once the time comes for restarting surgical practices. One approach would emphasize on prioritizing the highest cardio-metabolic risk populations chasing protective metabolic and cardiovascular effects of bariatric surgery. According to this approach, patients with uncontrolled diabetes, on high-dose insulin, with macro- and micro-vascular complications of diabetes, heart failure, severe sleep apnea, or BMI > 60 kg/m2 should have expedited access to bariatric surgery. On the other hand, the cornerstone of our approach is based on safety concerns considering the potential risk of poor outcomes if a patient were to develop postoperative COVID-19 infection. Our group believes a more aggressive approach assumes a safety profile we have yet to establish and may overlook the effect this could have on infrastructure that still continues to struggle with resources to combat COVID-19 despite the widespread cessation of elective procedures. Our structured approach focuses on slow and selective restarting of surgical practice until we learn more about the impact of COVID-19 on bariatric surgical patients. Another point of view taken by some is questioning the current timing of reinstituting bariatric surgery in certain places. Given the heterogeneous approach in opening up states and healthcare infrastructure across the USA, this tends to be a more challenging and existential argument. This question gets to the very core of what bariatric and metabolic surgery achieves in its patients, mainly improvement of metabolic derangements and the effects on end-organ dysfunction through comprehensive, surgical-driven weight loss strategies. Many states are still experiencing significant COVID-19 hospitalization numbers and strains on their systems. Other states, like Ohio, are moving into phased approaches of reintroducing healthcare functions. In Ohio, recent guidelines by the governor recommended proceeding with already delayed non-emergent cases if they met any of a list of conditions, including the threat of permanent dysfunction of an organ system, risk of rapidly worsening or severe symptoms, or presence of severe symptoms causing an inability to perform activities of daily living [20]. These types of definitions are also core principles in how these patients were insurance approved based on medical necessity. Regardless, based on definitions in our state, programs are now starting to move forward with bariatric cases and this calls for thoughtful approaches with real-time data analysis. We recommend that all surgical programs across the USA familiarize themselves with their local and state COVID-19 data reports, case projections, resource analyses, and government-mandated orders and protocols as these data will help guide them through the programmatic reintroduction process. As seen in Table 1, the application of the proposed tiered safety protocol split the current cohort of approved patients into three very manageable groups from an institutional resource utilization standpoint. Currently, we have 38 patients comprising the tier 1 group and we feel this will be a useful number of patients to analyze as we consider the safety profile of bariatric surgery in the midst of the COVID-19 pandemic. This will allow us to assess for suitability of transition to the next tier based on tier 1 perioperative outcomes, local epidemiological factors, and hospital resources when that time arrives. Herein, we present a practical protocol for the triage of bariatric surgery patients as we aim for the safe reintroduction of non-urgent surgery in the USA in an active COVID-19 environment. This protocol contains core principles and considerations that should be useful for all surgical specialties as they consider similar paths toward programmatic reanimation and can serve as a template in analyzing tiered outcomes in real time.
  14 in total

1.  Predicting risk for serious complications with bariatric surgery: results from the Michigan Bariatric Surgery Collaborative.

Authors:  Jonathan F Finks; Kerry L Kole; Panduranga R Yenumula; Wayne J English; Kevin R Krause; Arthur M Carlin; Jeffrey A Genaw; Mousumi Banerjee; John D Birkmeyer; Nancy J Birkmeyer
Journal:  Ann Surg       Date:  2011-10       Impact factor: 12.969

2.  Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission.

Authors:  Jennifer Lighter; Michael Phillips; Sarah Hochman; Stephanie Sterling; Diane Johnson; Fritz Francois; Anna Stachel
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079

3.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

Review 4.  Chest CT and Coronavirus Disease (COVID-19): A Critical Review of the Literature to Date.

Authors:  Constantine A Raptis; Mark M Hammer; Ryan G Short; Amar Shah; Sanjeev Bhalla; Andrew J Bierhals; Peter D Filev; Michael D Hope; Jean Jeudy; Seth J Kligerman; Travis S Henry
Journal:  AJR Am J Roentgenol       Date:  2020-04-16       Impact factor: 3.959

5.  Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity.

Authors:  Ali Aminian; Alexander Zajichek; David E Arterburn; Kathy E Wolski; Stacy A Brethauer; Philip R Schauer; Michael W Kattan; Steven E Nissen
Journal:  JAMA       Date:  2019-10-01       Impact factor: 56.272

6.  Bariatric Surgical Practice During the Initial Phase of COVID-19 Outbreak.

Authors:  Ali Aminian; Mohammad Kermansaravi; Shahriar Azizi; Peyman Alibeigi; Sina Safamanesh; Ali Mousavimaleki; Mohammad Taghi Rezaei; Maziar Faridi; Somayeh Mokhber; Abdolreza Pazouki; Saeed Safari
Journal:  Obes Surg       Date:  2020-09       Impact factor: 4.129

7.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

8.  Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection.

Authors:  Shaoqing Lei; Fang Jiang; Wating Su; Chang Chen; Jingli Chen; Wei Mei; Li-Ying Zhan; Yifan Jia; Liangqing Zhang; Danyong Liu; Zhong-Yuan Xia; Zhengyuan Xia
Journal:  EClinicalMedicine       Date:  2020-04-05

9.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

10.  COVID-19 Outbreak and Surgical Practice: Unexpected Fatality in Perioperative Period.

Authors:  Ali Aminian; Saeed Safari; Abdolali Razeghian-Jahromi; Mohammad Ghorbani; Conor P Delaney
Journal:  Ann Surg       Date:  2020-07       Impact factor: 13.787

View more
  6 in total

1.  Impact of the COVID-19 Pandemic on Patient Fertility Care.

Authors:  Karen N DSouza; Minerva Orellana; Alessandra J Ainsworth; Gabrielle Cummings; Kirsten A Riggan; Chandra C Shenoy; Megan A Allyse
Journal:  J Patient Exp       Date:  2022-05-06

2.  Obesity and Metabolic Surgery Society of India (OSSI) Recommendations for Bariatric and Metabolic Surgery Practice During the COVID-19 Pandemic.

Authors:  Sandeep Aggarwal; Kamal Mahawar; Manish Khaitan; Praveen Raj; Randeep Wadhawan; NandaKishore Dukkipati; Kuldeepak S Kular; Arun Prasad; Aparna Govil Bhasker; Vandana Soni; Brijesh Madhok; Sarfaraz Baig; Raj Palaniappan; H V Shivaram; Deep Goel; Vivek Bindal; Sukhvinder Saggu; Rajesh Shrivastava; Sumeet Shah; Shrihari Dhorepatil; Rajesh Khullar
Journal:  Obes Surg       Date:  2020-08-22       Impact factor: 4.129

3.  The Forgotten Element in the Resumption of Elective Bariatric Surgery During the COVID-19 Pandemic: the Patient Consent!

Authors:  Mohammed Said; Hosam Hamed
Journal:  Obes Surg       Date:  2020-09-19       Impact factor: 4.129

4.  Bariatric surgery for metabolic unhealthy obesity (MUO) during the COVID era: short-term results of a high-volume center.

Authors:  Valeria Guglielmi; Michela Campanelli; Emanuela Bianciardi; Domenico Benavoli; Luca Colangeli; Monica D'Adamo; Paolo Sbraccia; Paolo Gentileschi
Journal:  Eat Weight Disord       Date:  2022-07-19       Impact factor: 3.008

5.  The First Modified Delphi Consensus Statement for Resuming Bariatric and Metabolic Surgery in the COVID-19 Times.

Authors:  Sjaak Pouwels; Islam Omar; Sandeep Aggarwal; Ali Aminian; Luigi Angrisani; Jose María Balibrea; Mohit Bhandari; L Ulas Biter; Robin P Blackstone; Miguel A Carbajo; Catalin A Copaescu; Jerome Dargent; Mohamed Hayssam Elfawal; Mathias A Fobi; Jan-Willem Greve; Eric J Hazebroek; Miguel F Herrera; Jacques M Himpens; Farah A Hussain; Radwan Kassir; David Kerrigan; Manish Khaitan; Lilian Kow; Jon Kristinsson; Marina Kurian; Rami Edward Lutfi; Rachel L Moore; Patrick Noel; Mahir M Ozmen; Jaime Ponce; Gerhard Prager; Sanjay Purkayastha; Juan Pujol Rafols; Almino C Ramos; Rui J S Ribeiro; Nasser Sakran; Paulina Salminen; Asim Shabbir; Scott A Shikora; Rishi Singhal; Peter K Small; Craig J Taylor; Antonio J Torres; Carlos Vaz; Yury Yashkov; Kamal Mahawar
Journal:  Obes Surg       Date:  2020-08-01       Impact factor: 4.129

6.  30-Day Morbidity and Mortality of Bariatric Surgery During the COVID-19 Pandemic: a Multinational Cohort Study of 7704 Patients from 42 Countries.

Authors:  Rishi Singhal; Christian Ludwig; Gavin Rudge; Georgios V Gkoutos; Abd Tahrani; Kamal Mahawar; Michał Pędziwiatr; Piotr Major; Piotr Zarzycki; Athanasios Pantelis; Dimitris P Lapatsanis; Georgios Stravodimos; Chris Matthys; Marc Focquet; Wouter Vleeschouwers; Antonio G Spaventa; Carlos Zerrweck; Antonio Vitiello; Giovanna Berardi; Mario Musella; Alberto Sanchez-Meza; Felipe J Cantu; Fernando Mora; Marco A Cantu; Abhishek Katakwar; D Nageshwar Reddy; Haitham Elmaleh; Mohammad Hassan; Abdelrahman Elghandour; Mohey Elbanna; Ahmed Osman; Athar Khan; Laurent Layani; Nalini Kiran; Andrey Velikorechin; Maria Solovyeva; Hamid Melali; Shahab Shahabi; Ashish Agrawal; Apoorv Shrivastava; Ankur Sharma; Bhavya Narwaria; Mahendra Narwaria; Asnat Raziel; Nasser Sakran; Sergio Susmallian; Levent Karagöz; Murat Akbaba; Salih Zeki Pişkin; Ahmet Ziya Balta; Zafer Senol; Emilio Manno; Michele Giuseppe Iovino; Ahmed Osman; Mohamed Qassem; Sebastián Arana-Garza; Heitor P Povoas; Marcos Leão Vilas-Boas; David Naumann; Jonathan Super; Alan Li; Basil J Ammori; Hany Balamoun; Mohammed Salman; Amrit Manik Nasta; Ramen Goel; Hugo Sánchez-Aguilar; Miguel F Herrera; Adel Abou-Mrad; Lucie Cloix; Guilherme Silva Mazzini; Leonardo Kristem; Andre Lazaro; Jose Campos; Joaquín Bernardo; Jesús González; Carlos Trindade; Octávio Viveiros; Rui Ribeiro; David Goitein; David Hazzan; Lior Segev; Tamar Beck; Hernán Reyes; Jerónimo Monterrubio; Paulina García; Marine Benois; Radwan Kassir; Alessandro Contine; Moustafa Elshafei; Sueleyman Aktas; Sylvia Weiner; Till Heidsieck; Luis Level; Silvia Pinango; Patricia Martinez Ortega; Rafael Moncada; Victor Valenti; Ivan Vlahović; Zdenko Boras; Arnaud Liagre; Francesco Martini; Gildas Juglard; Manish Motwani; Sukhvinder Singh Saggu; Hazem Al Moman; Luis Adolfo Aceves López; María Angelina Contreras Cortez; Rodrigo Aceves Zavala; Christine D'Haese; Ivo Kempeneers; Jacques Himpens; Andrea Lazzati; Luca Paolino; Sarah Bathaei; Abdulkadir Bedirli; Aydın Yavuz; Çağrı Büyükkasap; Safa Özaydın; Andrzej Kwiatkowski; Katarzyna Bartosiak; Maciej Walędziak; Antonella Santonicola; Luigi Angrisani; Paola Iovino; Rossella Palma; Angelo Iossa; Cristian Eugeniu Boru; Francesco De Angelis; Gianfranco Silecchia; Abdulzahra Hussain; Srivinasan Balchandra; Izaskun Balciscueta Coltell; Javier Lorenzo Pérez; Ashok Bohra; Altaf K Awan; Brijesh Madhok; Paul C Leeder; Sherif Awad; Waleed Al-Khyatt; Ashraf Shoma; Hosam Elghadban; Sameh Ghareeb; Bryan Mathews; Marina Kurian; Andreas Larentzakis; Gavriella Zoi Vrakopoulou; Konstantinos Albanopoulos; Ahemt Bozdag; Azmi Lale; Cuneyt Kirkil; Mursid Dincer; Ahmad Bashir; Ashraf Haddad; Leen Abu Hijleh; Bruno Zilberstein; Danilo Dallago de Marchi; Willy Petrini Souza; Carl Magnus Brodén; Hjörtur Gislason; Kamran Shah; Antonio Ambrosi; Giovanna Pavone; Nicola Tartaglia; S Lakshmi Kumari Kona; K Kalyan; Cesar Ernesto Guevara Perez; Miguel Alberto Forero Botero; Adrian Covic; Daniel Timofte; Madalina Maxim; Dashti Faraj; Larissa Tseng; Ronald Liem; Gürdal Ören; Evren Dilektasli; Ilker Yalcin; Hudhaifa AlMukhtar; Mohammed Al Hadad; Rasmi Mohan; Naresh Arora; Digvijaysingh Bedi; Claire Rives-Lange; Jean-Marc Chevallier; Tigran Poghosyan; Hugues Sebbag; Lamia Zinaï; Saadi Khaldi; Charles Mauchien; Davide Mazza; Georgiana Dinescu; Bernardo Rea; Fernando Pérez-Galaz; Luis Zavala; Anais Besa; Anna Curell; Jose M Balibrea; Carlos Vaz; Luis Galindo; Nelson Silva; José Luis Estrada Caballero; Sergio Ortiz Sebastian; João Caetano Dallegrave Marchesini; Ricardo Arcanjo da Fonseca Pereira; Wagner Herbert Sobottka; Felipe Eduardo Fiolo; Matias Turchi; Antonio Claudio Jamel Coelho; Andre Luis Zacaron; André Barbosa; Reynaldo Quinino; Gabriel Menaldi; Nicolás Paleari; Pedro Martinez-Duartez; Gabriel Martínez de Aragon Ramírez de Esparza; Valentin Sierra Esteban; Antonio Torres; Jose Luis Garcia-Galocha; Miguel Josa; Jose Manuel Pacheco-Garcia; Maria Angeles Mayo-Ossorio; Pradeep Chowbey; Vandana Soni; Hercio Azevedo de Vasconcelos Cunha; Michel Victor Castilho; Rafael Meneguzzi Alves Ferreira; Thiago Alvim Barreiro; Alexandros Charalabopoulos; Elias Sdralis; Spyridon Davakis; Benoit Bomans; Giovanni Dapri; Koenraad Van Belle; Mazen Takieddine; Pol Vaneukem; Esma Seda Akalın Karaca; Fatih Can Karaca; Aziz Sumer; Caghan Peksen; Osman Anil Savas; Elias Chousleb; Fahad Elmokayed; Islam Fakhereldin; Hany Mohamed Aboshanab; Talal Swelium; Ahmad Gudal; Lamees Gamloo; Ayushka Ugale; Surendra Ugale; Clara Boeker; Christian Reetz; Ibrahim Ali Hakami; Julian Mall; Andreas Alexandrou; Efstratia Baili; Zsolt Bodnar; Almantas Maleckas; Rita Gudaityte; Cem Emir Guldogan; Emre Gundogdu; Mehmet Mahir Ozmen; Deepti Thakkar; Nandakishore Dukkipati; Poonam Shashank Shah; Shashank Subhashchandra Shah; Simran Shashank Shah; Md Tanveer Adil; Periyathambi Jambulingam; Ravikrishna Mamidanna; Douglas Whitelaw; Md Tanveer Adil; Vigyan Jain; Deepa Kizhakke Veetil; Randeep Wadhawan; Antonio Torres; Max Torres; Tabata Tinoco; Wouter Leclercq; Marleen Romeijn; Kelly van de Pas; Ali K Alkhazraji; Safwan A Taha; Murat Ustun; Taner Yigit; Aatif Inam; Muhammad Burhanulhaq; Abdolreza Pazouki; Foolad Eghbali; Mohammad Kermansaravi; Amir Hosein Davarpanah Jazi; Mohsen Mahmoudieh; Neda Mogharehabed; Gregory Tsiotos; Konstantinos Stamou; Francisco J Barrera Rodriguez; Marco A Rojas Navarro; Omar MOhamed Torres; Sergio Lopez Martinez; Elda Rocio Maltos Tamez; Gustavo A Millan Cornejo; Jose Eduardo Garcia Flores; Diya Aldeen Mohammed; Mohamad Hayssam Elfawal; Asim Shabbir; Kim Guowei; Jimmy By So; Elif Tuğçe Kaplan; Mehmet Kaplan; Tuğba Kaplan; DangTuan Pham; Gurteshwar Rana; Mojdeh Kappus; Riddish Gadani; Manish Kahitan; Koshish Pokharel; Alan Osborne; Dimitri Pournaras; James Hewes; Errichetta Napolitano; Sonja Chiappetta; Vincenzo Bottino; Evelyn Dorado; Axel Schoettler; Daniel Gaertner; Katharina Fedtke; Francisco Aguilar-Espinosa; Saul Aceves-Lozano; Alessandro Balani; Carlo Nagliati; Damiano Pennisi; Andrea Rizzi; Francesco Frattini; Diego Foschi; Laura Benuzzi; Chirag Parikh; Harshil Shah; Enrico Pinotti; Mauro Montuori; Vincenzo Borrelli; Jerome Dargent; Catalin A Copaescu; Ionut Hutopila; Bogdan Smeu; Bart Witteman; Eric Hazebroek; Laura Deden; Laura Heusschen; Sietske Okkema; Theo Aufenacker; Willem den Hengst; Wouter Vening; Yonta van der Burgh; Ahmad Ghazal; Hamza Ibrahim; Mourad Niazi; Bilal Alkhaffaf; Mohammad Altarawni; Giovanni Carlo Cesana; Marco Anselmino; Matteo Uccelli; Stefano Olmi; Christine Stier; Tahsin Akmanlar; Thomas Sonnenberg; Uwe Schieferbein; Alejandro Marcolini; Diego Awruch; Marco Vicentin; Eduardo Lemos de Souza Bastos; Samuel Azenha Gregorio; Anmol Ahuja; Tarun Mittal; Roel Bolckmans; Tom Wiggins; Clément Baratte; Judith Aron Wisnewsky; Laurent Genser; Lynn Chong; Lillian Taylor; Salena Ward; Lynn Chong; Lillian Taylor; Michael W Hi; Helen Heneghan; Naomi Fearon; Andreas Plamper; Karl Rheinwalt; Helen Heneghan; Justin Geoghegan; Kin Cheung Ng; Naomi Fearon; Krzysztof Kaseja; Maciej Kotowski; Tarig A Samarkandy; Adolfo Leyva-Alvizo; Lourdes Corzo-Culebro; Cunchuan Wang; Wah Yang; Zhiyong Dong; Manel Riera; Rajesh Jain; Hosam Hamed; Mohammed Said; Katia Zarzar; Manuel Garcia; Ahmet Gökhan Türkçapar; Ozan Şen; Edoardo Baldini; Luigi Conti; Cacio Wietzycoski; Eduardo Lopes; Tadeja Pintar; Jure Salobir; Cengiz Aydin; Semra Demirli Atici; Anıl Ergin; Huseyin Ciyiltepe; Mehmet Abdussamet Bozkurt; Mehmet Celal Kizilkaya; Nezihe Berrin Dodur Onalan; Mariana Nabila Binti Ahmad Zuber; Wei Jin Wong; Amador Garcia; Laura Vidal; Marc Beisani; Jorge Pasquier; Ramon Vilallonga; Sharad Sharma; Chetan Parmar; Lyndcie Lee; Pratik Sufi; Hüseyin Sinan; Mehmet Saydam
Journal:  Obes Surg       Date:  2021-07-30       Impact factor: 4.129

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.